Medical Tech Outlook Weekly Brief
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Medical Tech Outlook
In the global fight against HIV, one of the greatest clinical challenges is detecting the virus. While standard diagnostic tests, focused on PCR viral RNA or antigens/ antibodies, excel at identifying active infection, they fall dangerously short when it comes to uncovering HIV reservoirs—dormant cells where the virus hides in its DNA into the host cells. These reservoirs evade even the most aggressive antiretroviral therapy (ART) and remain the silent threat behind viral rebound and ART failure. Without visibility into these hidden strongholds, clinicians are left in the dark. A patient may show undetectable viral loads, yet still harbor the seeds of resurgence. A diagnostic blind spot like this undermines efforts toward a functional cure and limits how the success of ART treatment is truly measured. SUPBIO’s HIV-1 DNA Quantitative Detection Kit delivers the breakthrough that the HIV Diagnostics field has long awaited. By directly quantifying total HIV-1 DNA, it provides an unprecedented window into early infection, the viral reservoir, transforming how disease progression is tracked, how ART treatment is evaluated and how care is personalized for long-term outcomes. This capability is nothing short of pivotal—as it empowers clinicians to track the size of the HIV reservoir over the entire course of infection, offering visibility into how effectively ART is suppressing the virus at its genomic source. By directly measuring the hidden viral burden, SUPBIO’s kit equips physicians with data they have never had before, enabling more informed, precision-driven treatment decisions. Clinicians can now optimize the timing of therapy initiation, modification, or de-escalation, thereby reducing unnecessary exposure to the long-term side effects of ART while maintaining viral control. For the research community, this precision unlocks a consistent, reproducible method for evaluating experimental therapies aimed at reservoir eradication, closing one of the most persistent measurement gaps in HIV cure research. More than a diagnostic tool, SUPBIO’s kit also reimagines how ART response is monitored in real time. By enabling longitudinal comparison of HIV-1 DNA and RNA levels, it reveals subtle shifts in reservoir decay and flags emerging risks. Persistent HIV-1 DNA becomes a powerful early indicator—not just of therapeutic resistance, but of early diagnosis of infection, potential immune dysfunction or impending virologic rebound. This transforms treatment from reactive crisis management to proactive, data-guided care.
Historically, keeping a wound dry was considered the quickest way to heal chronic wounds. However, with decades of research and studies and endless effort by the industry, a moist wound healing theory and system have been established over the last 30 years. This requires wound dressings to absorb the exudates and provide a moist environment to achieve optimum healing effects. Taking advantage of this new theory, Foshan United Medical Technologies Ltd. (UMT), a prominent technology company specializing in designing and manufacturing advanced wound care products for acute and chronic injuries, has become the vanguard of recently emerged manufacturers of advanced wound care products. UMT achieved this by improving the standards of wound care products and pursuing better product performance through innovations. Driven by managing director Dr. Xiaodong Wang’s 30- plus years of experience in research and development, manufacturing management, quality control, compliance, and customer service, the firm has become an industry leader with a solid foundation for success. UMT’s wound care prowess is powered by its emphasis on using high-quality materials to build products of exceptional quality and impeccable regulatory compliance. One of the company’s competencies is the fibrous materials—alginate, chitosan, and carboxymethyl cellulose (CMC), which serve as the basis for delivering outstanding results. Alginate, derived from seaweed, is renowned for its exceptional absorbency properties. UMT has brought alginate wound dressings to a higher standard with significant fluid handling capability that enables efficient absorption and creates a moist healing environment for chronic wounds. Similarly, the company’s CMC-driven products possess exceptional absorbency and form a soft gel upon contact with wound fluid or water. This unique material promotes gentle and effective moisture absorption for a favorable healing environment. UMT has also developed a patented chitosan wound dressing that overcomes chitosan’s conventional limitations and modifies the material’s absorbency and bacteriostatic properties, delivering a unique and effective way to stop bleeding and promote healing. These attributes are particularly beneficial for wound care, as bleeding and infection risks are expected when the skin is compromised.
Osteoarthritis affects 10 percent of the global population aged 60 and above, and with the elderly population projected to double by 2050, it is expected to be the leading cause of disability by 2030. This poses the question, how is the global orthopedic community planning to prevent this future? Kaiser Technology, a medical equipment manufacturing company, aims to answer this through its comprehensive range of surgical instruments designed to holistically support orthopedic surgery. These include surgical tools, equipment for surgeon protection, patient care, and post-surgical rehabilitation, among others. “Our commitment to patient well-being encompasses every stage of their treatment, where we strive to ensure they receive the best care possible, from the moment they enter our care to the point of achieving successful recovery,” says Belén Chen, medical advisor of Kaiser Technology. Delving into its latest developments, Belén highlights Kaiser’s Warming and Cooling Therapy with Compression and how it combines the best competencies of existing treatment methodologies to deliver better patient outcomes. Cooling and heating are typically used to treat acute and chronic injuries. The current marketplace is brimming with cooling and heating solutions, including ice or hot packs, hydrocollator packs, whirlpools (cold or warm), ice machines, and infrared lamps. But all of them have drawbacks. A prevalent one is their fixing on localized body parts, which complicates the maintenance of a steady temperature and leads to additional issues. Kaiser’s solution bridges these gaps by equipping clinicians with the ability to better control the temperature, time, and compression. The machine uses cold therapy to effectively reduce swelling, inflammation, and pain, whereas its heating capabilities increase muscle elasticity and blood flow while decreasing pain and joint stiffness. Powered by solid features, the device is poised to expand Kaiser’s applicability across a broader range of medical needs, particularly in the sports medicine and rehabilitation domains. An outstanding illustration of the effectiveness of warming and cooling with compression therapy is demonstrated by Dr. Charles Cook, who applied the device to a lymphedema patient following surgery.
In Vitro Diagnostics
Michael Baron, Executive Director of Clinical Laboratory Operations, Wisconsin Diagnostic Laboratories
In Vitro Diagnostic
Will Roden, MBA, MHA, BSN, RN, NE-BC, AACC, FACHE, Administrative Director of Cardiovascular Services/Practice Administrator, Augusta Health
Regenerative Medicine
Carol Chow, Head of Pharmacy & Research, Gleneagles Hospital Hong Kong
Regenerative Medicine
Natalie Yang, Senior Medical Staff Association Chair, Austin Health
Regenerative Medicine
Janene Lawrence, Clinical Nurse Manager (Medical), Hutt Valley DHB
In Vitro Diagnostic
Esther May Cheam Sue San, Senior Nurse Manager, Thomson Hospital Kota Damansara
Regenerative Medicine
Christopher Leo, Chairman, Medicine Cluster, Raffles Medical Group
Disposable Healthcare Solutions Driving Safety and Access
Driven by these forces, APAC’s Disposable Orthopedic Surgical Products market is projected to reach $2.34 billion by 2030 (9.1 percent CAGR), Wound and Skin Care Products to $4.93 billion (4.8 percent CAGR), and HIV in vitro diagnostic kits to $487.7 billion by 2028 (2.57 percent CAGR).
The magazine features thought leadership articles from Esther May Cheam Sue San, Senior Nurse Manager at Thomson Hospital Kota Damansara, highlighting how integrating AI with ESG practices in critical care enhances ICU efficiency and reduces environmental impact. Michael Baron, Executive Director of Clinical Laboratory Operations at Wisconsin Diagnostic Laboratories, sheds light on the emerging trend of alternative workforce development models in clinical laboratories.
In this edition featuring APAC’s best disposable orthopedic surgical products manufacturer, wound and skin care products and HIV in vitro diagnostic kits, we hope you find the right partner to meet your organization’s needs.
